669 related articles for article (PubMed ID: 24833752)
1. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model.
Lora-Tamayo J; Murillo O; Bergen PJ; Nation RL; Poudyal A; Luo X; Yu HY; Ariza J; Li J
J Antimicrob Chemother; 2014 Sep; 69(9):2434-42. PubMed ID: 24833752
[TBL] [Abstract][Full Text] [Related]
2. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.
Ly NS; Bulitta JB; Rao GG; Landersdorfer CB; Holden PN; Forrest A; Bergen PJ; Nation RL; Li J; Tsuji BT
J Antimicrob Chemother; 2015 May; 70(5):1434-42. PubMed ID: 25712313
[TBL] [Abstract][Full Text] [Related]
3. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.
Bergen PJ; Tsuji BT; Bulitta JB; Forrest A; Jacob J; Sidjabat HE; Paterson DL; Nation RL; Li J
Antimicrob Agents Chemother; 2011 Dec; 55(12):5685-95. PubMed ID: 21911563
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
[TBL] [Abstract][Full Text] [Related]
5. In vitro pharmacokinetics/pharmacodynamics of continuous ceftazidime infusion alone and in combination with colistin against Pseudomonas aeruginosa biofilm.
Gómez-Junyent J; Murillo O; Yu HH; Azad MAK; Wickremasinghe H; Rigo-Bonnin R; Benavent E; Ariza J; Li J
Int J Antimicrob Agents; 2021 Feb; 57(2):106246. PubMed ID: 33253904
[TBL] [Abstract][Full Text] [Related]
6. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of
Mataraci Kara E; Yilmaz M; İstanbullu Tosun A; Özbek Çelik B
Infect Dis (Lond); 2020 Sep; 52(9):616-624. PubMed ID: 32427010
[No Abstract] [Full Text] [Related]
7. In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.
Park GC; Choi JA; Jang SJ; Jeong SH; Kim CM; Choi IS; Kang SH; Park G; Moon DS
Ann Lab Med; 2016 Mar; 36(2):124-30. PubMed ID: 26709259
[TBL] [Abstract][Full Text] [Related]
8. The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model.
Deris ZZ; Yu HH; Davis K; Soon RL; Jacob J; Ku CK; Poudyal A; Bergen PJ; Tsuji BT; Bulitta JB; Forrest A; Paterson DL; Velkov T; Li J; Nation RL
Antimicrob Agents Chemother; 2012 Oct; 56(10):5103-12. PubMed ID: 22802247
[TBL] [Abstract][Full Text] [Related]
9. Increased bactericidal activity of colistin on Pseudomonas aeruginosa biofilms in anaerobic conditions.
Kolpen M; Appeldorff CF; Brandt S; Mousavi N; Kragh KN; Aydogan S; Uppal HA; Bjarnsholt T; Ciofu O; Høiby N; Jensen PØ
Pathog Dis; 2016 Feb; 74(1):ftv086. PubMed ID: 26458402
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic characterization and colistin susceptibilities of carbapenem-resistant of Pseudomonas aeruginosa and Acinetobacter spp.
Mohanty S; Maurya V; Gaind R; Deb M
J Infect Dev Ctries; 2013 Nov; 7(11):880-7. PubMed ID: 24240048
[TBL] [Abstract][Full Text] [Related]
11. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
Hu YF; Liu CP; Wang NY; Shih SC
BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of meropenem extended infusion vs intermittent bolus monotherapy and in combination with colistin against Pseudomonas aeruginosa biofilm.
Benavent E; Ulldemolins M; El Haj C; Rigo-Bonnin R; Yu H; Wang L; Wickremasinghe H; Ariza J; Murillo O
Int J Antimicrob Agents; 2023 Aug; 62(2):106856. PubMed ID: 37211260
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
[TBL] [Abstract][Full Text] [Related]
14. In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method.
He W; Kaniga K; Lynch AS; Flamm RK; Davies TA
Diagn Microbiol Infect Dis; 2012 Dec; 74(4):417-9. PubMed ID: 22995366
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial susceptibility patterns of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii against carbapenems, colistin, and tigecycline.
Somily AM; Absar MM; Arshad MZ; Al Aska AI; Shakoor ZA; Fatani AJ; Siddiqui YM; Murray TS
Saudi Med J; 2012 Jul; 33(7):750-5. PubMed ID: 22821309
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing.
Mohamed AF; Cars O; Friberg LE
J Antimicrob Chemother; 2014 May; 69(5):1350-61. PubMed ID: 24474432
[TBL] [Abstract][Full Text] [Related]
17. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
Walsh CC; Landersdorfer CB; McIntosh MP; Peleg AY; Hirsch EB; Kirkpatrick CM; Bergen PJ
J Antimicrob Chemother; 2016 Aug; 71(8):2218-29. PubMed ID: 27118778
[TBL] [Abstract][Full Text] [Related]
18. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.
Bergen PJ; Forrest A; Bulitta JB; Tsuji BT; Sidjabat HE; Paterson DL; Li J; Nation RL
Antimicrob Agents Chemother; 2011 Nov; 55(11):5134-42. PubMed ID: 21876058
[TBL] [Abstract][Full Text] [Related]
19. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
Bergen PJ; Li J; Nation RL; Turnidge JD; Coulthard K; Milne RW
J Antimicrob Chemother; 2008 Mar; 61(3):636-42. PubMed ID: 18227094
[TBL] [Abstract][Full Text] [Related]
20. Evaluation in vitro of the efficacy of colistin methanesulfonate against biofilm-forming multidrug-resistant Pseudomonas aeruginosa (MDRP).
Marumo K; Komukai D; Hirose M; Nakamura H; Tanaka H; Ugajin K; Nagashima G; Yoshimura A
J Infect Chemother; 2013 Apr; 19(2):348-51. PubMed ID: 22872187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
